Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticlePROCEEDINGS OF THE 19TH ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES, 5 December 2015 (Tokyo, Japan)

Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes the Expansion of Human Promyelocytic Leukemia Cell Line, NB4

RYOHEI KOIDE, KASEM KULKEAW, YUKA TANAKA, ANTHONY SWAIN, YOICHI NAKANISHI and DAISUKE SUGIYAMA
Anticancer Research July 2016, 36 (7) 3635-3643;
RYOHEI KOIDE
1Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KASEM KULKEAW
1Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKA TANAKA
2Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
3Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTHONY SWAIN
1Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
2Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
4Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOICHI NAKANISHI
4Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAISUKE SUGIYAMA
1Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
4Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
5Center for Advanced Medical Innovation, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ds-mons{at}yb3.so-net.ne.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 36 no. 7 3635-3643
PMID 
27354634

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received April 5, 2016
  • Revision received May 20, 2016
  • Accepted May 24, 2016
  • Published online June 27, 2016.

Copyright & Usage 
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. RYOHEI KOIDE1,
  2. KASEM KULKEAW1,
  3. YUKA TANAKA2,3,
  4. ANTHONY SWAIN1,2,4,
  5. YOICHI NAKANISHI4 and
  6. DAISUKE SUGIYAMA1,4,5⇑
  1. 1Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
  2. 2Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  3. 3Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  4. 4Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
  5. 5Center for Advanced Medical Innovation, Kyushu University, Fukuoka, Japan
  1. Correspondence to: Daisuke Sugiyama, MD, Ph.D., Center for Advanced Medical Innovation, Kyushu University, 3-1-1 Higashi-ku, Fukuoka, 812-8582, Japan. Tel: +81 926426210 ext. 6210, Fax: +81 926426146, e-mail: ds-mons{at}yb3.so-net.ne.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 2 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 36, Issue 7
July 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes the Expansion of Human Promyelocytic Leukemia Cell Line, NB4
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes the Expansion of Human Promyelocytic Leukemia Cell Line, NB4
RYOHEI KOIDE, KASEM KULKEAW, YUKA TANAKA, ANTHONY SWAIN, YOICHI NAKANISHI, DAISUKE SUGIYAMA
Anticancer Research Jul 2016, 36 (7) 3635-3643;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes the Expansion of Human Promyelocytic Leukemia Cell Line, NB4
RYOHEI KOIDE, KASEM KULKEAW, YUKA TANAKA, ANTHONY SWAIN, YOICHI NAKANISHI, DAISUKE SUGIYAMA
Anticancer Research Jul 2016, 36 (7) 3635-3643;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Pdx1 expression in hematopoietic cells activates Kras-mutation to drive leukemia in KC (Pdx1-Cre ; LSL-KrasG12D/+) mice
  • Google Scholar

More in this TOC Section

  • DBA Lectin Binds to Highly Proliferative Mouse Erythroleukemia Cells
  • Dewaxed Brown Rice Contains a Significant Amount of Lipopolysaccharide Pointing to Macrophage Activation via TLRs
  • Effect of Lipopolysaccharide Derived from Pantoea agglomerans on the Phagocytic Activity of Amyloid β by Primary Murine Microglial Cells
Show more PROCEEDINGS OF THE 19TH ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES, 5 December 2015 (Tokyo, Japan)

Keywords

  • aryl hydrocarbon receptor
  • StemRegenin 1
  • NB4 cells
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire